OSTEOP
MCID: OST002
MIFTS: 74

Osteoporosis (OSTEOP)

Categories: Bone diseases, Fetal diseases, Genetic diseases, Rare diseases

Aliases & Classifications for Osteoporosis

MalaCards integrated aliases for Osteoporosis:

Name: Osteoporosis 57 38 12 76 75 37 55 6 43 44 15 63 40 73
Postmenopausal Osteoporosis 75 29 6
Osteoporosis, Postmenopausal 57 73
Osteoporosis, Involutional 57 13
Bone Mineral Density Quantitative Trait Locus; Bmnd 57
Bone Mineral Density Variation Qtl, Osteoporosis 57
Bone Mineral Density, Quantitative Trait Locus 40
Bone Mineral Density Quantitative Trait Locus 57
Osteoporosis, Postmenopausal, Susceptibility 57
Osteoporosis, Susceptibility to 57
Osteoporosis Postmenopausal 55
Involutional Osteoporosis 75
Osteoporosis, Senile 73
Senile Osteoporosis 75
Osteop 75
Bmnd 57

Characteristics:

OMIM:

57
Inheritance:
autosomal dominant


HPO:

32
osteoporosis:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

OMIM 57 166710
Disease Ontology 12 DOID:11476
ICD10 33 M81.0 M80.0
ICD9CM 35 733.0 733.00
MeSH 44 D010024
NCIt 50 C3298
SNOMED-CT 68 64859006
KEGG 37 H01593
SNOMED-CT via HPO 69 263681008

Summaries for Osteoporosis

MedlinePlus : 43 Osteoporosis is a disease that thins and weakens the bones. Your bones become fragile and break easily, especially the bones in the hip, spine, and wrist. In the United States, millions of people either already have osteoporosis or are at high risk due to low bone mass. Anyone can develop osteoporosis, but it is more common in older women. Risk factors include Getting older Being small and thin Having a family history of osteoporosis Taking certain medicines Being a white or Asian woman Having low bone density Osteoporosis is a silent disease. You might not know you have it until you break a bone. A bone mineral density test is the best way to check your bone health. To keep bones strong, eat a diet rich in calcium and vitamin D, exercise, and do not smoke. If needed, medicines can also help. It is also important to try to avoid falling down. Falls are the number one cause of fractures in older adults. NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases

MalaCards based summary : Osteoporosis, also known as postmenopausal osteoporosis, is related to osteoporosis, juvenile and glucocorticoid-induced osteoporosis, and has symptoms including tremor, angina pectoris and back pain. An important gene associated with Osteoporosis is COL1A2 (Collagen Type I Alpha 2 Chain), and among its related pathways/superpathways are Osteoclast differentiation and Mineral absorption. The drugs Alendronate and Etidronic acid have been mentioned in the context of this disorder. Affiliated tissues include Bone and Bone, and related phenotypes are osteoporosis and hematopoietic system

Disease Ontology : 12 A bone resorption disease characterized by decreased density of normally mineralized bone which results in the thinning of bone tissue and decreased mechanical strength.

UniProtKB/Swiss-Prot : 75 Osteoporosis: A systemic skeletal disorder characterized by decreased bone mass and deterioration of bone microarchitecture without alteration in the composition of bone. The result is fragile bones and an increased risk of fractures, even after minimal trauma. Osteoporosis is a chronic condition of multifactorial etiology and is usually clinically silent until a fracture occurs.

PubMed Health : 63 About osteoporosis: Having weak bones that easily break is a sign of osteoporosis. It is normal for your bones to become less dense as you grow older, but osteoporosis speeds up this process. This condition can particularly lead to problems in older age because broken bones do not heal as easily in older people as they do in young people, and the consequences are more serious. In general, osteoporosis is more common in women, and they often develop it at a younger age.Getting older does not mean that you will automatically develop osteoporosis, but the risk does increase with age. People over the age of 70 are more likely to have low bone density. Plus, the risk of falling increases in old age, which then also makes fractures more likely.But there are several things you can do to protect and strengthen your bones – even if you are already older.

Wikipedia : 76 Osteoporosis is a disease where increased bone weakness increases the risk of a broken bone. It is the... more...

Description from OMIM: 166710

Related Diseases for Osteoporosis

Diseases in the Osteoporosis family:

Osteoporosis, Juvenile Juvenile Primary Osteoporosis
Lrp5-Related Primary Osteoporosis

Diseases related to Osteoporosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 581)
# Related Disease Score Top Affiliating Genes
1 osteoporosis, juvenile 34.9 WNT1 LRP5 COL1A1 CALCA BGLAP
2 glucocorticoid-induced osteoporosis 34.4 TNFSF11 TNFRSF11B RUNX2 CALCA BGLAP
3 bone mineral density quantitative trait locus 15 33.2 CALCR PDLIM4
4 bone disease 32.6 VDR TNFSF11 TNFRSF11B TNFRSF11A RUNX2 LRP5
5 rickets 32.6 BGLAP SLC34A1 VDR
6 osteopetrosis 32.4 LRP5 TNFRSF11A TNFSF11
7 osteogenesis imperfecta, type viii 31.9 COL1A1 COL1A2
8 osteoporotic fracture 31.5 COL1A1 ESR1 TNFRSF11B
9 bone resorption disease 31.4 VDR TNFSF11 TNFRSF11B TNFRSF11A RUNX2 LRP5
10 osteonecrosis 31.4 BGLAP RUNX2 TNFRSF11B TNFSF11
11 osteomalacia 31.1 BGLAP CALCA VDR
12 hyperparathyroidism 31.1 BGLAP CALCA TNFRSF11B VDR
13 periodontitis 31.0 BGLAP RUNX2 TNFRSF11B TNFSF11
14 periodontal disease 30.9 TNFRSF11A TNFRSF11B TNFSF11
15 brittle bone disorder 30.9 BGLAP COL1A1 COL1A2
16 paget's disease of bone 30.8 BGLAP CALCA TNFRSF11A TNFRSF11B TNFSF11
17 primary hyperparathyroidism 30.7 BGLAP CALCA VDR
18 secondary hyperparathyroidism of renal origin 30.7 BGLAP CALCA TNFRSF11B VDR
19 chronic kidney failure 30.6 BGLAP CALCA TNFRSF11B VDR
20 hyperostosis 30.6 COL1A1 LRP5 TNFRSF11B
21 otosclerosis 30.4 COL1A1 COL1A2 TNFRSF11B
22 idiopathic hypercalciuria 30.4 BGLAP TNFSF11 VDR
23 renal osteodystrophy 30.3 BGLAP CALCA TNFRSF11B VDR
24 hemophilic arthropathy 30.3 TNFRSF11A TNFRSF11B TNFSF11
25 periodontitis, chronic 30.3 TNFRSF11B TNFSF11
26 bone cancer 30.1 COL1A1 ESR1 TNFRSF11A TNFSF11
27 ankylosis 30.0 BGLAP RUNX2 TNFRSF11B
28 hyperphosphatemia 30.0 RUNX2 SLC34A1 VDR
29 protrusio acetabuli 30.0 ESR1 VDR
30 kummell's disease 29.9 TNFRSF11B TNFSF11
31 bone mineral density quantitative trait locus 1 12.7
32 osteoporosis-pseudoglioma syndrome 12.7
33 bone mineral density quantitative trait locus 17 12.7
34 bone mineral density quantitative trait locus 9 12.6
35 bone mineral density quantitative trait locus 10 12.6
36 bone mineral density quantitative trait locus 11 12.6
37 bone mineral density quantitative trait locus 13 12.6
38 bone mineral density quantitative trait locus 14 12.6
39 bone mineral density quantitative trait locus 4 12.6
40 bone mineral density quantitative trait locus 2 12.6
41 bone mineral density quantitative trait locus 5 12.6
42 bone mineral density quantitative trait locus 6 12.6
43 bone mineral density quantitative trait locus 7 12.6
44 juvenile primary osteoporosis 12.4
45 nephrolithiasis/osteoporosis, hypophosphatemic, 1 12.3
46 nephrolithiasis/osteoporosis, hypophosphatemic, 2 12.3
47 osteoporosis and oculocutaneous hypopigmentation syndrome 12.2
48 growth failure, microcephaly, mental retardation, cataracts, large joint contractures, osteoporosis, cortical dysplasia, and cerebellar atrophy 12.1
49 amino aciduria with mental deficiency, dwarfism, muscular dystrophy, osteoporosis, and acidosis 12.0
50 macroepiphyseal dysplasia with osteoporosis, wrinkled skin, and aged appearance 12.0

Comorbidity relations with Osteoporosis via Phenotypic Disease Network (PDN): (show top 50) (show all 87)


Active Peptic Ulcer Disease Acute Cor Pulmonale
Acute Cystitis Alzheimer Disease
Anxiety Aortic Atherosclerosis
Aortic Valve Disease 1 Asthma
Benign Essential Hypertension Bronchiectasis
Bronchitis Bronchopneumonia
Cerebral Atherosclerosis Cerebral Degeneration
Cerebrovascular Disease Chronic Myocardial Ischemia
Chronic Pulmonary Heart Disease Chylomicron Retention Disease
Conjunctivitis Conn's Syndrome
Cystitis Decubitus Ulcer
Deficiency Anemia Dermatomycosis
Dyskinesia of Esophagus Dysthymic Disorder
Esophagitis Femoral Vein Thrombophlebitis
Gastroesophageal Reflux Generalized Anxiety Disorder
Generalized Atherosclerosis Heart Disease
Hyperparathyroidism Hypertension, Essential
Hyperuricemia, Pulmonary Hypertension, Renal Failure, and Alkalosis Syndrome Hypothyroidism
Idiopathic Interstitial Pneumonia Inflammatory Bowel Disease 1
Intervertebral Disc Disease Intestinal Obstruction
Iron Deficiency Anemia Irritable Bowel Syndrome
Macular Degeneration, Age-Related, 1 Major Depressive Disorder
Marasmus Monoclonal Paraproteinemia
Neurogenic Bladder Nutritional Deficiency Disease
Opioid Addiction Oral Candidiasis

Graphical network of the top 20 diseases related to Osteoporosis:



Diseases related to Osteoporosis

Symptoms & Phenotypes for Osteoporosis

Symptoms via clinical synopsis from OMIM:

57
Skel:
postmenopausal osteoporosis


Clinical features from OMIM:

166710

Human phenotypes related to Osteoporosis:

32
# Description HPO Frequency HPO Source Accession
1 osteoporosis 32 HP:0000939

UMLS symptoms related to Osteoporosis:


tremor, angina pectoris, back pain, sciatica, pelvic pain, equilibration disorder, muscle cramp

MGI Mouse Phenotypes related to Osteoporosis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.07 CALCR COL1A1 ESR1 LRP5 RUNX2 TNFRSF11A
2 immune system MP:0005387 10.02 CALCR COL1A1 ESR1 LRP5 RUNX2 TNFRSF11A
3 craniofacial MP:0005382 10.01 COL1A1 LRP5 RUNX2 TNFRSF11A TNFRSF11B TNFSF11
4 limbs/digits/tail MP:0005371 9.96 CALCR COL1A1 COL1A2 ESR1 LRP5 RUNX2
5 mortality/aging MP:0010768 9.93 CALCR COL1A1 COL1A2 ESR1 LRP5 RUNX2
6 muscle MP:0005369 9.56 COL1A1 COL1A2 ESR1 RUNX2 SLC34A1 TNFSF11
7 skeleton MP:0005390 9.4 CALCR COL1A1 COL1A2 ESR1 LRP5 RUNX2

Drugs & Therapeutics for Osteoporosis

PubMedHealth treatment related to Osteoporosis: 63

Even if someone already has osteoporosis, it is important for them to do regular exercise and get enough calcium and vitamin D. In Germany, statutory health insurances cover the cost of calcium or vitamin D supplements if a doctor has prescribed them.Osteoporosis can be treated with several drugs designed to slow bone loss and increase the production of new bone tissue. These include bisphosphonates and some hormonal or hormone-like medications. These kinds of drugs can have different types of side effects, though, and may not be suitable for everyone. They are only considered if someone has already broken a bone, or if their risk of bone fractures is high – for example, if their bone density is very low or if they have a combination of different risk factors, like low body weight, old age and a higher risk of falling.Hormone products, like those used to treat menopause symptoms, can also lower the risk of osteoporosis-related bone fractures when taken over the long term. But long-term hormone therapy during or after menopause increases the risk of cardiovascular diseases and breast cancer. For this reason it is only rarely recommended as treatment for osteoporosis. The pros and cons of this treatment should be carefully weighed.

Drugs for Osteoporosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 659)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Alendronate Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 66376-36-1, 121268-17-5 2088
2
Etidronic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 7414-83-7, 2809-21-4 3305
3
Tocopherol Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 1406-66-2 14986
4
Benzocaine Approved, Investigational Phase 4,Phase 3,Not Applicable 94-09-7, 1994-09-7 2337
5 tannic acid Approved Phase 4,Phase 3,Not Applicable
6
Linagliptin Approved Phase 4,Phase 3 668270-12-0 10096344
7
Pioglitazone Approved, Investigational Phase 4,Phase 2 111025-46-8 4829
8
Teriparatide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 52232-67-4 16133850
9
Calcium Carbonate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 471-34-1
10
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-28-2 5757
11
Polyestradiol phosphate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 28014-46-2
12
Medroxyprogesterone acetate Approved, Investigational Phase 4,Phase 3,Phase 1 71-58-9
13
Progesterone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 57-83-0 5994
14 Estradiol valerate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 979-32-8
15
Zoledronic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 118072-93-8 68740
16
Letrozole Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 112809-51-5 3902
17
Emtricitabine Approved, Investigational Phase 4,Phase 2,Phase 3 143491-57-0 60877
18
Denosumab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 615258-40-7
19
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 53-03-2 5865
20
Testosterone enanthate Approved Phase 4,Phase 2,Phase 3 315-37-7 9416
21
Testosterone Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 58-22-0 6013
22
Testosterone undecanoate Approved, Investigational Phase 4,Phase 2,Phase 3 5949-44-0
23
Methyltestosterone Approved Phase 4,Phase 2,Phase 3 58-18-4 6010
24
Bazedoxifene Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 198481-32-2
25
Racepinephrine Approved Phase 4,Phase 2,Phase 3,Not Applicable,Early Phase 1 329-65-7 838
26
Epinephrine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable,Early Phase 1 51-43-4 5816
27
rituximab Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 174722-31-7 10201696
28
leucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58-05-9 6006 143
29
Anastrozole Approved, Investigational Phase 4,Phase 3,Phase 2 120511-73-1 2187
30
Tetracycline Approved, Vet_approved Phase 4,Phase 2 60-54-8 5353990
31
Demeclocycline Approved Phase 4,Phase 2 127-33-3 5311063
32
Phytonadione Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 84-80-0 4812 5284607
33
Tibolone Approved, Investigational Phase 4,Phase 3,Phase 2 5630-53-5
34
Esomeprazole Approved, Investigational Phase 4,Phase 1,Not Applicable 161796-78-7, 119141-88-7 4594 9579578
35
Fluvastatin Approved Phase 4 93957-54-1 1548972
36
Acetaminophen Approved Phase 4,Phase 3,Phase 1,Not Applicable 103-90-2 1983
37
Liraglutide Approved Phase 4,Early Phase 1 204656-20-2 44147092
38
Pamidronate Approved Phase 4,Phase 2,Phase 1,Not Applicable 40391-99-9 4674
39
Fluticasone Approved, Experimental Phase 4 90566-53-3 62924
40
Potassium Citrate Approved, Investigational, Vet_approved Phase 4,Phase 3,Not Applicable
41
Pregabalin Approved, Illicit, Investigational Phase 4 148553-50-8 5486971
42
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
43
Angiotensin II Approved, Investigational Phase 4 11128-99-7, 68521-88-0, 4474-91-3 172198 65143
44
Gliclazide Approved Phase 4 21187-98-4 3475
45
Vildagliptin Approved, Investigational Phase 4 274901-16-5 6918537
46
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 83-43-2 6741
47
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 302-25-0
48
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 50-24-8 5755
49
Basiliximab Approved, Investigational Phase 4 152923-56-3, 179045-86-4
50
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Phase 2,Not Applicable 2921-57-5

Interventional clinical trials:

(show top 50) (show all 1916)
# Name Status NCT ID Phase Drugs
1 Efficacy and Safety of Brand Versus Generic Alendronate for Osteoporosis Treatment Unknown status NCT02371252 Phase 4 Generic alendronate
2 Osteoporosis and Dental Implant Unknown status NCT00727493 Phase 4 alendronate once weekly 70mg;placebo
3 Efficacy and Safety Study of Risedronate, Cholecalciferol Combination Tablet in Patients With Osteoporosis Unknown status NCT01675297 Phase 4 Risedronate/Cholecalciferol combination;Risedronate
4 Determination of Vitamin D Dose to Maintain Sufficiency Amongst Indian and Malay Women in the Tropics Unknown status NCT02389179 Phase 4 Vitamin D3
5 A One-year Randomized Controlled Trial Evaluating the Impact of Pioglitazone Versus Linagliptin on Bone Turnover Markers Unknown status NCT02429232 Phase 4 Pioglitazone;Linagliptin
6 Clinical Comparison of Efficacy and Safety of Two Teriparatide Formulations: Osteofortil and Forteo Unknown status NCT01945788 Phase 4 Teriparatide (rDNA origin)
7 The Effect of Inactive and Active Vitamin D on Serum Sclerostin/dickkopf1 Levels Unknown status NCT01765010 Phase 4 Calcitriol;Alfacalcidol;Cholecalciferol;Placebo
8 Analgesic Effects of the Gastrolith, in Osteoporotic Patients Suffering From Recent Skeletal Pain Caused by Vertebral Fractures Unknown status NCT01482858 Phase 4
9 Effects of Omega-3 Fatty Acids on Bone and Frailty Unknown status NCT00634686 Phase 4
10 Effect of Evogliptin on Bone Metabolism in Human Unknown status NCT02587975 Phase 4 Evogliptin
11 Short-term Functional Recovery Between Early- and Late Bisphosphonate Treatment Following Hemiarthroplasty Unknown status NCT02148848 Phase 4 Risedronate
12 Multi-centre Clinical Trial on Hormone Replacement Treatment in China Unknown status NCT01698164 Phase 4 estradiol plus MPA;Ximingting Tablet;estradiol plus progesterone
13 The Effect of Zoledronic Acid to Bone Fusion and Bone Metabolism of Patients With Lumbar Degenerative Disease After Lumbar Interbody Fusion Unknown status NCT01310465 Phase 4 zoledronic acid;sodium chloride
14 The Effect of Vitamin D Supplementation on Calcium Excretion in Thalassemia: a Dose Response Study Unknown status NCT01323608 Phase 4 Vitamin D3;Placebo
15 Multi-center Clinical Study of Guli Capsules in the Treatment of Knee Osteoarthritis Unknown status NCT02484508 Phase 4 Guli capsule;Kangguzengsheng capsule
16 Evaluation of Predictive Factors Regarding the Effectivity of Aromatase Inhibitor Therapy (PreFace) Unknown status NCT01908556 Phase 4 Letrozole
17 Alendronate for Vascular Calcification in Peritoneal Dialysis Patients? Unknown status NCT00299572 Phase 4 alendronate (Fosamax)
18 Alendronate for Prevention of AntiRetroviral Therapy-associated Bone Loss Unknown status NCT02322099 Phase 4 Alendronate;Placebo;Tenofovir disoproxil
19 Clinical Study of Raloxifene and Strontium Ranelate in Postmenopausal Osteoporosis Completed NCT01544894 Phase 4 Raloxifene;Strontium ranelate
20 A Study of Adherence to Once Monthly Ibandronate (Bonviva) in Women With Post-Menopausal Osteoporosis, Supported by a Patient Relationship Program (PRP) Completed NCT00545363 Phase 4 Ibandronate
21 Enhancing Osteoporosis Therapy: Can We Open the Anabolic Window? Completed NCT01166958 Phase 4 Teriparatide;Raloxifene
22 Teriparatide Treatment in Patients With Inherited Osteoporosis Completed NCT01360424 Phase 4 Teriparatide
23 Effect of Full Length Parathyroid Hormone, PTH(1-84) or Strontium Ranelate on Bone Markers in Postmenopausal Women With Primary Osteoporosis (FP-006-IM) Completed NCT00479037 Phase 4 Full Length Parathyroid Hormone, PTH(1-84);Strontium Ranelate
24 Evaluation Of Missed Osteoporosis Diagnoses, And Preference Between Once Monthly Ibandronate And Once Weekly Alendronate Completed NCT00327990 Phase 4 Ibandronate;Alendronate
25 Denosumab in Current Users of Bisphosphonates for Glucocorticoid-induced Osteoporosis Completed NCT01465568 Phase 4 Denosumab;bisphosphonates
26 ExBonAdAsia Study: A Study of Once Monthly Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis. Completed NCT00545090 Phase 4 ibandronate [Bonviva/Boniva]
27 Risedronate and Parathyroid Hormone to Reverse Osteoporosis Caused by Chronic Steroid Use Completed NCT00221299 Phase 4 Risedronate;Parathyroid Hormone
28 A Study of Ibandronate (Boniva) to Evaluate Bone Turnover Markers in Women With Treatment-Naive Postmenopausal Osteoporosis Completed NCT02598934 Phase 4 Ibandronate
29 Danish Osteoporosis Prevention Study Completed NCT00252408 Phase 4 Hormone replacement therapy
30 A Study of Ibandronate (Boniva) to Evaluate Satisfaction in Women With Post-Menopausal Osteoporosis or Osteopenia Completed NCT02604836 Phase 4 Ibandronate
31 Effects of Teriparatide or Denosumab on Bone in Postmenopausal Women With Osteoporosis Completed NCT01753856 Phase 4 Teriparatide;Denosumab;Demeclocycline;Tetracycline;Calcium Supplement;Vitamin D
32 STEP: Study of Imaging Techniques (ImaTx and DXA) in Postmenopausal Women With OstEoporosis Using Preotact (FP-008-ES) Completed NCT00583518 Phase 4 Parathyroid hormone (PTH)
33 A Study of Ibandronate (Bonviva) in Patients With Post-Menopausal Osteoporosis Completed NCT02598440 Phase 4 Alendronate;Ibandronate
34 A Study of Teriparatide in Japanese Osteoporosis Patients Completed NCT01430104 Phase 4 Teriparatide;Aspara-CA 600 mg;Alfarol 1.0 µg
35 A Study of Prevention and Treatment of Postmenopausal Osteoporosis in Chinese Women Completed NCT00860964 Phase 4 Placebo;estradiol valerate
36 HRT Versus Etidronate for Osteoporosis and Fractures in Asthmatics Receiving Glucocorticoids. Completed NCT00376662 Phase 4 Hormone Replacement Therapy and Etidronate
37 High Dosage Vitamin D and Osteoporosis Completed NCT00491920 Phase 4 cholecalciferol (Vitamin D3);placebo
38 PRIOR Study - A Study of Ibandronate (Boniva) in Postmenopausal Women With Osteoporosis or Osteopenia Completed NCT02598453 Phase 4 Ibandronate
39 Prevention of Osteoporosis in Breast Cancer Survivors Completed NCT00567606 Phase 4
40 Study To Investigate Patient Preference On Dosing In Ibandronate And Risedronate In Korean Women With Postmenopausal Osteoporosis Completed NCT00405392 Phase 4 Ibandronate (SB743830HD)
41 Evaluation of the Effects of Teriparatide on Skeleton Images in Postmenopausal Women With Osteoporosis Completed NCT00259298 Phase 4 teriparatide
42 A Study of Once Monthly Bonviva (Ibandronate) in Prevention of Glucocorticoid-Induced Osteoporosis. Completed NCT00545051 Phase 4 Placebo;ibandronate
43 A Study of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis Previously Treated With Bonviva Completed NCT00081653 Phase 4 ibandronate [Bonviva/Boniva];ibandronate [Bonviva/Boniva]
44 BEATRIS Study: A Study of Adherence to Bonviva (Ibandronate) Once Monthly in Women With Post-Menopausal Osteoporosis Completed NCT00545909 Phase 4 ibandronate [Bonviva/Boniva];ibandronate [Bonviva/Boniva]
45 2-Year Therapy With Teriparatide vs 1-yr Therapy Followed by 1-Year of Raloxifene or Calcium/Vit D in Severe Postmenopausal Osteoporosis Completed NCT00191425 Phase 4 Teriparatide;Raloxifene
46 SUMMIT Study: A Study of Persistence to Bonviva (Ibandronate) Once Monthly in Women With Post-Menopausal Osteoporosis. Completed NCT00545480 Phase 4 ibandronate [Bonviva/Boniva];ibandronate [Bonviva/Boniva]
47 A Study of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis Who Have Received Previous Bonviva Treatment Completed NCT00551174 Phase 4 ibandronate [Bonviva/Boniva];ibandronate [Bonviva/Boniva]
48 A Study To Assess the Quality and Strength of Bone in Women Participants With Osteoporosis Taking Oral Ibandronate Versus Placebo Completed NCT00148915 Phase 4 ibandronate;Placebo
49 A Study of Bone Turnover Markers in Post-Menopausal Women With Osteoporosis Treated With Monthly Boniva (Ibandronate) Completed NCT00303485 Phase 4 Placebo;Vitamin D and calcium supplementation;ibandronate [Bonviva/Boniva]
50 Impact of Oral Ibandronate 150 mg Monthly on Structural Properties of Bone in Postmenopausal Osteoporosis (SPIMOS-3D) Completed NCT00271713 Phase 4 ibandronate, calcium and vitamin D;placebo,calcium and vitamin D

Search NIH Clinical Center for Osteoporosis

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Osteoporosis cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Osteoporosis:
PREOB�, autologous osteoblasts for bone disorders

Cochrane evidence based reviews: osteoporosis

Genetic Tests for Osteoporosis

Genetic tests related to Osteoporosis:

# Genetic test Affiliating Genes
1 Postmenopausal Osteoporosis 29 CALCR COL1A1 COL1A2 LRP5 PDLIM4 VDR

Anatomical Context for Osteoporosis

MalaCards organs/tissues related to Osteoporosis:

41
Bone, Breast, Prostate, Testes, Bone Marrow, Spinal Cord, Kidney
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Osteoporosis:
# Tissue Anatomical CompartmentCell Relevance
1 Bone Bone Marrow Mononucleated Osteoclasts Affected by disease
2 Bone Bone Marrow Multinucleated Osteoclasts Affected by disease
3 Blood Hematopoietic Bone Marrow Osteoclast Precursor Cells Affected by disease

Publications for Osteoporosis

Articles related to Osteoporosis:

(show top 50) (show all 6236)
# Title Authors Year
1
Evolving Role of MR Imaging and PET in Assessing Osteoporosis. ( 30420220 )
2019
2
Reduced TIPE2 expression is inversely associated with proinflammatory cytokines and positively correlated with bone mineral density in patients with osteoporosis. ( 30496728 )
2019
3
Low bone mineral density is associated with an elevated risk of developing increased arterial stiffness: A 10-year follow-up of Japanese women from the Japanese Population-based Osteoporosis (JPOS) cohort study. ( 30502749 )
2019
4
Retraction: Paper "Combined Treatment with Vitamin K₂ and Bisphosphonate in Postmenopausal Women with Osteoporosis" by Iwamoto J, et al. [Yonsei Med J 2003;44(5):751-756]. ( 30554498 )
2019
5
Retraction: Paper "Comparison of Effect of Treatment with Etidronate and Alendronate on Lumbar Bone Mineral Density in Elderly Women with Osteoporosis" by Iwamoto J, et al. [Yonsei Med J 2005;46(6):750-758]. ( 30554500 )
2019
6
Structural elucidation and anti-osteoporosis activities of polysaccharides obtained from Curculigo orchioides. ( 30318216 )
2019
7
Cardiovascular Autonomic Dysfunction: Link Between Multiple Sclerosis Osteoporosis and Neurodegeneration. ( 29429076 )
2018
8
Effects of quality indicator monitoring for glucocorticoid-induced osteoporosis and trends of drug treatment in a Japanese hospital. ( 29878618 )
2018
9
Denosumab or oral bisphosphonates in primary osteoporosis: a "real-life" study. ( 29340971 )
2018
10
Effects of the Phosphodiesterase-5 (PDE-5) Inhibitors, Avanafil and Zaprinast, on Bone Remodeling and Oxidative Damage in a Rat Model of Glucocorticoid-Induced Osteoporosis. ( 29557941 )
2018
11
Type 2 diabetes is associated with higher trabecular bone density but lower cortical bone density: the Vietnam Osteoporosis Study. ( 29967929 )
2018
12
Werner syndrome: a rare cause of osteoporosis in a young female. ( 29878212 )
2018
13
Does the Association of Comorbidity with 1-Year Mortality After Hip Fracture Differ According to Gender? The Norwegian Epidemiologic Osteoporosis Studies (NOREPOS). ( 29427505 )
2018
14
Real-world evidence of raloxifene versus alendronate in preventing non-vertebral fractures in Japanese women with osteoporosis: retrospective analysis of a hospital claims database. ( 28028633 )
2018
15
DEPTOR regulates osteogenic differentiation via inhibiting MEG3-mediated activation of BMP4 signaling and is involved in osteoporosis. ( 29973283 )
2018
16
Significant improvement of bone mineral density by denosumab without bisphosphonate pre-treatment in glucocorticoid-induced osteoporosis. ( 29251033 )
2018
17
Association Between Possible Osteoporosis and Shunt-Dependent Hydrocephalus After Subarachnoid Hemorrhage. ( 29946014 )
2018
18
Myricetin ameliorates glucocorticoid-induced osteoporosis through the ERK signaling pathway. ( 29883721 )
2018
19
Inhibiting Cellular Senescence: A New Therapeutic Paradigm for Age-Related Osteoporosis. ( 29425296 )
2018
20
The histone methyltransferase DOT1L inhibits osteoclastogenesis and protects against osteoporosis. ( 29348610 )
2018
21
Association of cystatin C- and creatinine-based eGFR with osteoporotic fracture in Japanese postmenopausal women with osteoporosis: sarcopenia as risk for fracture. ( 29464358 )
2018
22
A Serological Diagnosis of Coeliac Disease Is Associated with Osteoporosis in Older Australian Adults. ( 29966287 )
2018
23
Patient satisfaction and efficacy of switching from weekly bisphosphonates to monthly minodronate for treatment and prevention of glucocorticoid-induced osteoporosis in Japanese patients with systemic rheumatic diseases: a randomized, clinical trial. ( 29904824 )
2018
24
Serum levels of matrix metalloproteinase-3 and autoantibodies related to rheumatoid arthritis in the general Japanese population and their association with osteoporosis and osteoarthritis: the ROAD study. ( 28365812 )
2018
25
Geisinger high-risk osteoporosis clinic (HiROC): 2013-2015 FLS performance analysis. ( 29063214 )
2018
26
Bisphosphonate therapy for spinal osteoporosis in Hajdu-Cheney syndrome - new data and literature review. ( 29618366 )
2018
27
Gastrodin alleviates glucocorticoid induced osteoporosis in rats via activating the Nrf2 signaling pathways. ( 29545917 )
2018
28
The effects of denosumab and alendronate on glucocorticoid-induced osteoporosis in patients with glomerular disease: A randomized, controlled trial. ( 29543887 )
2018
29
Knowledge of risk factors and prevention of osteoporosis: the Israeli women's health at midlife study. ( 29959608 )
2018
30
Changes in bone mineral density and bone turnover markers during treatment with teriparatide in pregnancy- and lactation-associated osteoporosis. ( 29389010 )
2018
31
Glucocorticoid-Induced Osteoporosis: Management Challenges in Older Patients. ( 29941355 )
2018
32
Conservative surgical treatment of medication related osteonecrosis of the jaw (MRONJ) lesions in patients affected by osteoporosis exposed to oral bisphosphonates: 24 months follow-up. ( 29802059 )
2018
33
Functional analysis of p.Ala253_Leu254insAsn mutation in PLS3 responsible for X-linked osteoporosis. ( 28646489 )
2018
34
Tonsil-derived mesenchymal stem cell-embedded in situ crosslinkable gelatin hydrogel therapy recovers postmenopausal osteoporosis through bone regeneration. ( 29975738 )
2018
35
The increase in bone mineral density by bisphosphonate with active vitamin D analogue is associated with the serum calcium level within the reference interval in postmenopausal osteoporosis. ( 29451049 )
2018
36
Progesterone for the prevention and treatment of osteoporosis in women. ( 29962257 )
2018
37
Image of the Micro-Computed Tomography and Atomic-Force Microscopy of Bone in Osteoporosis Animal Model. ( 29954487 )
2018
38
Orthosiphon stamineus (Misai Kucing) ameliorated postmenopausal osteoporosis in rat model. ( 28926512 )
2018
39
Effects of osteoporosis drug treatments on cortical and trabecular bone in the femur using DXA-based 3D modeling. ( 29974136 )
2018
40
Increased risk of osteoporosis in patients with primary biliary cirrhosis. ( 29543880 )
2018
41
Mito-micea88 and mitochondrial DNA mutator mice as models of human osteoporosis caused not by aging but by hyperparathyroidism. ( 29973435 )
2018
42
Should women be screened for osteoporosis at midlife? ( 29447485 )
2018
43
Abaloparatide is an Effective Treatment Option for Postmenopausal Osteoporosis: Review of the Number Needed to Treat Compared with Teriparatide. ( 29951742 )
2018
44
Psychometric properties and assessment of the Osteoporosis Health Belief Scale among the general Arabic population. ( 29440877 )
2018
45
miR-542-3p prevents ovariectomy-induced osteoporosis in rats via targeting SFRP1. ( 29319176 )
2018
46
Glucocorticoid-induced osteoporosis: an update. ( 29691807 )
2018
47
Does industry-sponsored education foster overdiagnosis and overtreatment of depression, osteoporosis and over-active bladder syndrome? An Australian cohort study. ( 29440213 )
2018
48
Preservation of type H vessels and osteoblasts by enhanced preosteoclast platelet-derived growth factor type BB attenuates glucocorticoid-induced osteoporosis in growing mice. ( 29800693 )
2018
49
Epigallocatechin-3-Gallate Ameliorates Glucocorticoid-Induced Osteoporosis of Rats <i>in Vivo</i> and <i>in Vitro</i>. ( 29867459 )
2018
50
Referral patterns to an osteoporosis clinic for dermatology patients undergoing prolonged corticosteroid therapy. ( 29447676 )
2018